The GRAPPA and OMERACT (Outcome Measures in Rheumatology Clinical Trials) group are continually striving to optimise the assessment and management of psoriatic arthritis (PsA). As part of these ongoing efforts, the group performed two independent surveys one to healthcare professionals with an interest in psoriatic arthritis (PsA) and one to patients with PsA in January of this year. Following this, a face to face meeting of 25 experts including 5 patients was held in February 2017. Now we are asking for your help again with a follow up survey. This provides some feedback from the previous surveys where we explored current disease activity measures in PsA.
At the meeting, we developed some recommendations for measuring disease activity in research studies and routine clinical practice and we would value your review of these to see if you support the recommendations made. To help us gather further insights into effective and meaningful measures for disease activity in PsA the GRAPPA Working Group* would very much appreciate a few minutes of your time to complete this short survey.
The survey can be completed by following this link